Literature DB >> 19141401

Expression of matrix metalloproteinase-9 in the neoplastic and interstitial inflammatory infiltrate cells in the different histopathological types of esophageal cancer.

Barbara Mroczko1, Mirosław Kozłowski, Magdalena Groblewska, Marta Lukaszewicz, Jacek Nikliński, Jerzy Laudański, Lech Chyczewski, Maciej Szmitkowski.   

Abstract

Metalloproteinase-9 (MMP-9) is the proteolytic enzyme degrading type IV collagen, and plays important role in the invasiveness and metastatic potential of tumor cells. The aim of the current study was to compare the association between the intensity of MMP-9 expression in neoplastic cells and in the interstitial inflammatory infiltrate cells in esophageal cancer with clinicopathological features of esophageal cancer (EC) and in different histopatological types of EC, e.g. adenocarcinoma and esophageal squamous cell carcinoma. The study included 32 EC patients, 17 cases of squamous cell carcinoma and 15 cases of adenocarcinoma, verified histopatologically. The presence of MMP-9 in cancer tissue was investigated by immunohistochemistry on formalin-fixed, wax-embedded sections of esophageal cancers. The light microscopy was used to evaluate the expression of metalloproteinase-9 in cancer cells and in inflammatory infiltrate in the neoplastic interstitium in semi-quantitative scale. The expression of MMP-9 in cancer cells was positive in 81% of cases whereas in inflammatory cells - in 75% and increased with tumor stage, depth of tumor invasion (T factor) and lymph node metastases (N factor). In squamous cell cancer the MMP-9 expression in cancer cells and in inflammatory infiltrate was higher than those in adenocarcinoma. Mean value of MMP-9 expression in inflammatory cells was higher in early stages of EC, whereas mean expression of this enzyme in cancer cells increased with tumor stage. In conclusion, this is the first study comparing the expression of metalloproteinase-9 in cancer and inflamatory infiltrate cells in different histopatological types of esophageal cancer. We proved the synthesis of MMP-9 by cancer cells as well as by inflammatory cells and its correlation with tumor stage, tumor size, depth of tumor invasion and lymph node metastases. The results suggest the role of MMP-9 in esophageal tumorigenesis, although this issue requires further investigations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19141401     DOI: 10.2478/v10042-008-0065-9

Source DB:  PubMed          Journal:  Folia Histochem Cytobiol        ISSN: 0239-8508            Impact factor:   1.698


  5 in total

1.  MMP-1 is a (pre-)invasive factor in Barrett-associated esophageal adenocarcinomas and is associated with positive lymph node status.

Authors:  Martin Grimm; Maria Lazariotou; Stefan Kircher; Luisa Stuermer; Christoph Reiber; Andreas Höfelmayr; Stefan Gattenlöhner; Christoph Otto; Christoph T Germer; Burkhard H A von Rahden
Journal:  J Transl Med       Date:  2010-10-14       Impact factor: 5.531

2.  MMP-1/PAR-1 signal transduction axis and its prognostic impact in esophageal squamous cell carcinoma.

Authors:  Hong-Hua Peng; Xi Zhang; Pei-Guo Cao
Journal:  Braz J Med Biol Res       Date:  2011-11-16       Impact factor: 2.590

3.  Integrated molecular analysis reveals complex interactions between genomic and epigenomic alterations in esophageal adenocarcinomas.

Authors:  DunFa Peng; Yan Guo; Heidi Chen; Shilin Zhao; Kay Washington; TianLing Hu; Yu Shyr; Wael El-Rifai
Journal:  Sci Rep       Date:  2017-01-19       Impact factor: 4.379

4.  Esophageal cancer stem cells express PLGF to increase cancer invasion through MMP9 activation.

Authors:  Yue Chen; Tinghui Jiang; Aiwu Mao; Jianrong Xu
Journal:  Tumour Biol       Date:  2014-09-12

5.  Association of dietary intake, medication and anthropometric indices with serum levels of advanced glycation end products, caspase-3, and matrix metalloproteinase-9 in diabetic patients.

Authors:  Elaheh Foroumandi; Sorayya Kheirouri; Rahmat Nosrati; Ramin Ghodsi
Journal:  J Diabetes Metab Disord       Date:  2021-05-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.